Efficacy and safety of lenvatinib‐transcatheter arterial chemoembolization sequential therapy for hepatocellular carcinoma within the up‐to‐seven criteria
LEN-TACE sequential therapy may be a beneficial treatment for HCC within the up-to-seven criteria, especially for tumors other than the simple nodular type.
Authors
- Tomotake Shirono (ORCID: https://orcid.org/0000-0002-2662-6779)
- Masahito Nakano (ORCID: https://orcid.org/0000-0002-3375-180X)
- Hironori Koga (ORCID: https://orcid.org/0000-0001-5814-9543)
- Shigeo Shimose (ORCID: https://orcid.org/0000-0003-2068-8386)
- Etsuko Moriyama
- Masatoshi Tanaka (ORCID: https://orcid.org/0000-0002-4791-8885)
- Hideki Iwamoto (ORCID: https://orcid.org/0000-0001-5688-1335)
- Ryoko Kuromatsu
- Takashi Niizeki
- Takumi Kawaguchi (ORCID: https://orcid.org/0000-0002-7064-4325)
Institutions
- Kurume University (JP)
- ShinKokura Hospital (JP)
Publication Details
- Journal
- Hepatology Research
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1111/hepr.14193
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Chugai Pharmaceutical